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www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PMsuccesses were achieved in 95% of cases. Type B2/C lesions were treated in 63% of
cases. Long-term follow-up showed a combined major adverse cardiac events rate
(death, MI and target lesion revascularization (TLR)) of 11%. All cause mortality
was noted in 5%, cardiac mortality in 1%, MI in 6% and stroke in 1%. Finally, TLR
and target vessel revascularization were noted in 3% and 4% of cases respectively.
The independent predictors of MACE were cancer (Odds Ratio (OR): 6.55 [2.64,
16.28]; p<0.001), respiratory disease (OR: 4.41 [1.68, 10.47]; p<0.001), post-
dilation (OR: 2.85 [1.19-6.80]; p¼ 0.018) and type C lesions (OR: 1.91 [1.02-3.56];
p¼ 0.042).
Conclusions: In this real life cohort, the treatment of highly complex lesions with the
Osiro Stent was associated with excellent long-term results. Further randomized trials
are warranted to conﬁrm these ﬁndings.TCT-200
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Background: Long term safety and efﬁcacy of the Elixir DESyne BD Novolimus
Eluting Coronary Stent System (NECSS), a Co-Cr stent with a bioabsorbable polymer
compared to the control Endeavor Zotarolimus Eluting Coronary Stent System is not
known
Methods: 149 patients were randomized 3:1, either to the Elixir DESyne BD
Novolimus Eluting CSS loaded with 5mcg per mm of stent length of Novolimus,
a sirolimus metabolite, eluted via a bioabsorbable polylactide-based polymer, or to
the Endeavor Zotarolimus-eluting CSS (ZECSS) loaded with 10mcg per mm of
stent length of Zotarolimus eluted via a durable phosphoryl choline polymer. All
patients were analyzed for the primary endpoint of in-stent late lumen loss (LLL)
assessed by qualitative coronary angiography (QCA) at 6 months. Moreover, all
patients underwent evaluation for the secondary endpoints including the Device-
orientated Composite Endpoint (DoCE) deﬁned as: cardiac death, MI not clearly
attributable to a non-intervention vessel, and clinically-indicated target lesion
revascularization; clinically-indicated Target Vessel Revascularization (TVR), and
stent thrombosis at 1, 6, 9, and 12 months and annually through 5 years. Lesions
were also evaluated for angiographic endpoints at 6 months including: in-segment
LLL, percent diameter stenosis, minimal lumen diameter post-procedure, and
angiographic binary restenosis (ABR) (50%). A subset of patients underwent
intravascular ultrasound (IVUS) evaluation including percent (%) neointimal
obstruction at 6 months.
Results: The study met the primary endpoint demonstrating both non-inferiority and
superiority of the DESyne BD compared to the control (0.120.15 vs 0.670.47,
p<0.001), additionally, in-stent ABR was signiﬁcantly lower for DESyne BD (0% vs
7.9%, p¼0.003). Excellent clinical results at 6 months were demonstrated for both
devices (DoCE 2.7% vs. 3.2%, p¼ 1.00). Sustained low clinical event rates were
observed at 12 months and 24 months (DoCE 2.7% vs 3.2% p¼1.0)
Conclusions: The DESyne BD NECSS demonstrated sequential non-inferiority and
superiority over a durable polymer Endeavor ZECSS for in-stent late lumen loss at 6
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Background: The outcome of small-vessel stenting with the second-generation drug-
eluting stents (DES) remains uncertain. Stents deployed in small arteries, have
a higher metal-to-artery ratio; this may increase the risk of restenosis. Speciﬁc attri-
butes of stent design, including strut thickness and eluting drug, inﬂuence stent
performance characteristics, particularly in smaller coronary vessels.
Methods: This study is a single-center, retrospective observational study. From April
2009 to December 2011, 264 patients with small vessel coronary artery disease wereJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrtreated with 2.5mm DES implantation, which consisted of 225 patients with 2.5mm
Everolimus eluting stent (EES) implantation and 39 patients with 2.5mm Biolimus
eluting stent (BES) implantation. Out of these patients, 226 patients underwent follow-
up coronary angiography at eight months post-PCI. We evaluated the results of those
226 patients.
Results: Though pre-PCI reference vessel diameter were less in EES group than BES
group (EES:2.110.34, BES:2.250.28 mm, p<0.05), there were no signiﬁcant
difference in patient characteristics, pre-PCI minimal lumen diameter(MLD)
(0.690.36, 0.710.41 mm) and angiographic percent diameter sten-
osis(PDS)(67.817.1, 69.318.7 %). Post-PCI MLD of BES group were smaller than
those of EES group. (1.960.31, 2.080.31 mm p<0.05) Post-PCI PDS(11.010.9,
8.310.5 %) and acute gain(1.310.46, 1.440.47 mm) were similar in both groups.
At follow-up coronary angiography eight months later, there were no signiﬁcant
difference in MLD(1.850.55, 2.020.59 mm), PDS(21.620.7, 19.417.1 %),
binary restenosis (17 cases; 7.6%, 3 cases; 7.7%) and target lesion revacularization
(7 cases; 3%, 0 case; 0%).
Conclusions: Though pre-PCI lesion characteristics of BES group were a little better
than those of EES group, there were no signiﬁcant difference between EES and BES
in the middle-term outcome of small-vessel stenting.TCT-202
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Background: Pioglitazone is widely used for glycemic control in patients with type-2
diabetes mellitus (DM), and is associated with a lower risk of cardiovascular events
according to a meta-analysis of randomized trials. To evaluate the effect of pioglita-
zone on ischemic cardiovascular events in Japanese patients with DM and coronary
artery disease, after drug-eluting stents (DESs) implantation, the 12-month data from
the Japan-Drug Eluting Stents Evaluation; a Randomized Trial (J-DESsERT) was
analyzed.
Methods: In this prospective, multicenter trial, 3,533 patients were randomized 1:1
to undergo coronary stenting with Sirolimus-eluting stents or Paclitaxel-eluting
stents. Lesion lengths were 46 mm, with vessel diameters from 2.5 mm to 3.75
mm. Randomization was stratiﬁed based on the presence or absence of DM.
Deﬁnitions for allocation into the DM group at the time of this trial were: 1.
Previous DM diagnosis; 2. Currently on diabetic medication (oral hypoglycemic
drugs or insulin injections); 3. HbA1c (Japan diabetes society [JDS])  6.5% within
30 days before the procedure. Patients who met one or more of the above criteria
were allocated to the DM group. A total of 1,705 patients (48%) with DM were
analyzed from the J-DESsERT trial.
Results: Target vessel revascularization (TVR) is deﬁned as any ischemia-driven
repeat percutaneous coronary intervention (PCI), target vessel bypass surgery, all
death, myocardial infarction (Q wave and non-Q wave), and cerebrovascular
accident (stroke, transient ischemic attack). Including TVR, major adverse cardiac
cerebrovascular events (MACCE) occurred in only 22 of 357 patients (6.33%)
receiving pioglitazone at 12 months. Conversely, substantially more MACCE
events occurred in the group not receiving the pioglitazone, 152 of 1,348 patients
(11.6%, p¼<0.01).
Conclusions: Pioglitazone is associated with a signiﬁcantly lower MACCE rate at
both 8 and 12 months, in Japanese patients with DM, post-DES implantation.TCT-203
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Background: The purpose of this study was to evaluate the impact of second-
generation DES (2nd DES) as compared with ﬁrst-generation DES (1st DES) in
patients treated with DES implantation following rotational atherectomy (RA) for
heavily calciﬁed lesions.
Methods: From December 2003 to August 2012, 616 lesions in 492 patients were
treated with 1st DES (Sirolimus-eluting stent [SES] or Paclitaxel-eluting stent [PES])
or 2nd DES (Everolimus-eluting stent [EES] or Biolimus-eluting stent [BES])
implantations following RA exclusively and successfully. Of these lesions, 389
lesions in 312 (63.4%) patients who had undergone 8-month angiographic follow-up
were analysed.acts/POSTER/Bare Metal and Drug-Eluting Stent Studies B65
